IceCure Medical falls after FDA delays decision on breast cancer treatment system

Icecure Medical

20/03/2025 17:46

** Shares of Israel-based medical device maker IceCure Medical ICCM.O fall 17% to $1.22 in afternoon trading, their biggest one-day percentage fall in more than a year

** ICCM says it expects the FDA to make a decision on its  ProSense system, used for the treatment of a type of breast cancer, after Q1 2025

** Co previously expected FDA's decision by Q1 2025

** Co's ProSense provides a minimally invasive treatment option to destroy tumors by freezing them

** ICCM has risen 19.4% in the past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))